701
Participants
Start Date
September 15, 2017
Primary Completion Date
October 27, 2020
Study Completion Date
October 27, 2020
MabThera
Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
Korea University Ansan Hospital, Gyeonggi-do
St. Vincent's Hospital, Gyeonggi-do
Gachon University Gil Medical Center, Incheon
Chungnam National University Hospital, Daejeon
Keimyung University Dongsan Medical Center, Daegu
Yeungnam University Medical Center, Daegu
Ulsan University Hosiptal, Ulsan
Inje University Busan Paik Hospital, Busan
Pusan National University Hospital, Busan
Pusan National University Yangsan Hospital, Gyeongsangnam-do
Chonnam National University Hwasun Hospital, Jeollanam-do
Soon Chun Hyang University Hospital Bucheon, Bucheon-si
Daegu Catholic University Medical Center; Hematology, Daegu
Hallym University Sacred Heart Hospital; Department of Hematology, Gyeonggi-do
Inje University, Sanggye-Paik Hospital, Seoul
Korea University Anam Hospital, Seoul
Kangbuk Samsung Hospital, Seoul
Ewha Womans University Mokdong Hospital, Seoul
Seoul National University Hospital; Department of Oncology, Seoul
Severance Hospital, Yonsei University Health System; Oncology, Seoul
Samsung Medical Centre; Division of Hematology/Oncology, Seoul
St. Mary'S Hospital, the Catholic University School of Medicine; Internal Medicine, Seoul
Korea Cancer Center Hospital; Surgery, Seoul
Korea University Guro Hospital; Department of Hematology & Oncology, Seoul
SMG-SNU Boramae Medical Center, Seoul
Hoffmann-La Roche
INDUSTRY